NCT02128282 - Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma | Biotech Hunter

Enrollment

127

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

November 6, 2020

Study Completion Date

August 5, 2021

Conditions

Cholangiocarcinoma

Interventions

DRUG

CX-4945

API powder-in-capsule in 200 mg strength.

DRUG

Cisplatin

25 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.

DRUG

Gemcitabine

1,000 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21-day cycle.

Trial Locations (16)

32224

Mayo Clinic, Jacksonville

55905

Mayo Clinic, Rochester

75246

Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas

75702

Texas Oncology-Tyler, Tyler

80045

University of Colorado- Denver, Aurora

85259-5499

Mayo Clinic, Scottsdale

138-736

Asan Medical Center, Seoul

Unknown

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Severance Hospital, Yonsei University Health System, Seoul

Chang-Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung City

China Medical University Hospital, Taichung

National Cheng Kung University Hospitals, Tainan City

National Taiwan University Hospital, Taipei

Taipei Veterans General Hospital, Taipei

Chang-Gung Memorial Hospital - Linkou Branch, Taoyuan

All Listed Sponsors

lead

Senhwa Biosciences, Inc.

INDUSTRY